Accelerating Research and Development of Next Generation Malaria Vaccines Against Malaria A Model for Mosquito-Borne Diseases

The National Institutes of Health, through the National Institute of Allergy and Infectious Diseases, is planning a future funding opportunity to support the acceleration of research and development for next generation malaria vaccines. This forecasted grant opportunity reflects the federal government’s continued investment in combating infectious diseases with global health implications, particularly malaria and other mosquito-borne illnesses. The initiative is authorized under the Public Health Service Act and relevant federal regulations governing research grants, signaling a strong emphasis on scientific rigor, innovation, and public health impact. The primary purpose of this opportunity is to advance basic research, discovery, and preclinical development of highly effective malaria vaccines. The program specifically encourages innovative approaches that leverage recent technological advancements such as structure-based immunogen design and combination vaccine strategies. These approaches are intended to both reduce parasite infection rates and mitigate the overall disease burden caused by malaria. While the focus is on malaria, the broader objective includes developing models and insights applicable to other mosquito-borne diseases, thereby expanding the potential impact of funded research. Funding under this opportunity is expected to support a range of activities associated with early-stage vaccine development, including laboratory-based research, preclinical testing, and potentially translational efforts that bridge discovery and application. Although specific funding amounts, award ceilings, and total program funding have not yet been disclosed, the opportunity is categorized as a discretionary federal grant under the health funding category. There is no cost sharing or matching requirement, which may broaden accessibility for eligible applicants and reduce financial barriers to participation. Eligibility for this grant is extensive and inclusive, encompassing a wide range of domestic and international entities. Eligible applicants include federal agencies, state and local governments, institutions of higher education (both public and private), nonprofit organizations regardless of 501(c)(3) status, small businesses, for-profit organizations, tribal governments and organizations, public housing authorities, school districts, and non-domestic entities such as foreign institutions. This broad eligibility framework reflects the global nature of malaria research and the need for diverse institutional participation. The application process is anticipated to follow standard NIH submission procedures, likely requiring applicants to prepare detailed research proposals, including scientific aims, methodology, budget justification, and institutional capabilities. While specific application components and evaluation criteria are not yet provided in the forecast, NIH grants typically assess scientific merit, innovation, feasibility, investigator qualifications, and alignment with program priorities. Applicants are expected to monitor the official posting for detailed instructions once the opportunity is formally released. The timeline for this opportunity is currently in a forecast stage. The estimated posting date is November 27, 2026, with an anticipated application due date of February 11, 2027. Awards are expected to be issued by December 1, 2027, with project start dates aligned to the same timeframe. As a forecasted opportunity, these dates are subject to change, and applicants are encouraged to engage early in preparation activities. For additional information or inquiries, applicants may contact the program via the provided email address, which is dedicated to malaria and other mosquito-borne disease initiatives. This forecast serves as an early notification to the research community, allowing institutions and investigators to begin conceptualizing proposals and forming collaborations in advance of the formal funding announcement.